scholarly journals Immediate release tablet formulation of varenicline salicylate and comparative pharmacokinetic study in human volunteers

2018 ◽  
Vol Volume 12 ◽  
pp. 3377-3392
Author(s):  
Seong Shin Kwak ◽  
Eun Seok Lee ◽  
Ho Yub Yoon ◽  
Chang Hyun Kim ◽  
Yoon Tae Goo ◽  
...  
Keyword(s):  
Pharmacokinetic Study ◽  
Immediate Release ◽  
Tablet Formulation ◽  
Comparative Pharmacokinetic ◽  
Human Volunteers ◽  
Release Tablet

scholarly journals Promising Swellable Floating Bupropion Tablets: Formulation, in vitro/in vivo Evaluation and Comparative Pharmacokinetic Study in Human Volunteers

2020 ◽  
Vol Volume 14 ◽  
pp. 2741-2757 ◽  
Author(s):  
Mahmoud Teaima ◽  
Magdi M. Abdel Hamid ◽  
Nabil A. Shoman ◽  
Bhaskara R. Jasti ◽  
Mohamed A. El-Nabarawi
Keyword(s):  
Pharmacokinetic Study ◽  
In Vivo Evaluation ◽  
Comparative Pharmacokinetic ◽  
Human Volunteers

scholarly journals Safety, Tolerability and Bioequivalence Assessment of a Dispersible Tablet Formulation of Pyrazinamide

2017 ◽  
Vol 9 (05) ◽  
Author(s):  
Atreyee Sarkar ◽  
Mrunal S. Davey ◽  
Atul Savalia ◽  
Shivanand Dhanure
Keyword(s):  
Adverse Events ◽  
Human Subjects ◽  
Immediate Release ◽  
Tablet Formulation ◽  
Pharmacokinetic Parameters ◽  
Human Volunteers ◽  
Dispersible Tablet ◽  
Two Parameters ◽  
Bioequivalence Assessment ◽  
Major Adverse Events

Pyrazinamide is a widely used drug for the treatment of tuberculosis. A 150 mg Dispersible Tablet (DT) formulation of the drug was prepared by Micro Labs, a generic drug company. The formulation was developed for easy administration into paediatric patients. It was tested for bioequivalence in healthy adult human volunteers in fasting condition. A total of 36 subjects were enrolled in the study and all the 36 subjects completed both the two periods of the study without showing major adverse events. The pharmacokinetic parameters determined for bioequivalence were Cmax and AUC0-t. The two parameters were within the limit of bioequivalence criteria. The 150 mg DT formulation developed by Micro Labs was found to be bioequivalent to 500 mg immediate release tablet formulation of Riemser Pharma. Both the formulations were safe and well tolerated among the tested human subjects. No major adverse events were observed.

scholarly journals Influence of immediate release tablet formulation on dissolution profile of paracetamol

2018 ◽  
Vol 5 (3) ◽  
pp. 705-714
Author(s):  
Nemanja Todorović ◽  
Svetlana Goločorbin-Kon ◽  
Kristina Kermeci ◽  
Jelena Jovičić-Bata ◽  
Nebojša Pavlović ◽  
...  
Keyword(s):  
Immediate Release ◽  
Tablet Formulation ◽  
Dissolution Profile ◽  
Release Tablet
Sign in / Sign up

Export Citation Format

Share Document